APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infectious Coryza Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Infectious Coryza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026192 pages

Choose your research edition.

Industry ResearchInfectious Coryza Vaccine Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Infectious Coryza Vaccine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Infectious Coryza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infectious Coryza Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Infectious Coryza Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Infectious Coryza Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Infectious Coryza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Infectious Coryza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Infectious Coryza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Infectious Coryza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Infectious Coryza Vaccine include Boehringer Ingelheim, Ceva Santé Animale, Zoetis, Harbin Pharmaceutical Group, Merck, Plyco Bioengineering Co., Ltd., Qilu Animal Health Products Co., Ltd., Qingdao Yibang Biological Engineering Co., Ltd. and Shandong Huahong Biological Engineering Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Infectious Coryza Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Infectious Coryza Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Infectious Coryza Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Infectious Coryza Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Infectious Coryza Vaccine Segment by Company

Boehringer Ingelheim

Ceva Santé Animale

Zoetis

Harbin Pharmaceutical Group

Merck

Plyco Bioengineering Co., Ltd.

Qilu Animal Health Products Co., Ltd.

Qingdao Yibang Biological Engineering Co., Ltd.

Shandong Huahong Biological Engineering Co., Ltd.

Shandong Lvdu Biological Technology Co., Ltd.

Tianjin Ruipu Biotechnology Co., Ltd.

Infectious Coryza Vaccine Segment by Type

Monovalent Vaccine

Bivalent Vaccine

Trivalent Vaccine

Infectious Coryza Vaccine Segment by Application

Retail

Online Sale

Others

Infectious Coryza Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Coryza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infectious Coryza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Coryza Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Infectious Coryza Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Infectious Coryza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Infectious Coryza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Infectious Coryza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Infectious Coryza Vaccine Industry Trends Table 2. Infectious Coryza Vaccine Industry Drivers Table 3. Infectious Coryza Vaccine Industry Opportunities and Challenges Table 4. Infectious Coryza Vaccine Industry Restraints Table 5. Global Infectious Coryza Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Infectious Coryza Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Infectious Coryza Vaccine Sales by Manufacturers (K Doses) & (2021-2026) Table 8. Global Infectious Coryza Vaccine Sales Market Share by Manufacturers Table 9. Global Infectious Coryza Vaccine Average Sales Price (US$/Dose) of Manufacturers (2021-2026) Table 10. Global Infectious Coryza Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Infectious Coryza Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Infectious Coryza Vaccine Manufacturers, Product Type & Application Table 13. Global Infectious Coryza Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Infectious Coryza Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Monovalent Vaccine Table 17. Major Manufacturers of Bivalent Vaccine Table 18. Major Manufacturers of Trivalent Vaccine Table 19. Global Infectious Coryza Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Doses) Table 20. Global Infectious Coryza Vaccine Sales by Type (2021-2026) & (K Doses) Table 21. Global Infectious Coryza Vaccine Sales by Type (2027-2032) & (K Doses) Table 22. Global Infectious Coryza Vaccine Sales Market Share by Type (2021-2026) Table 23. Global Infectious Coryza Vaccine Sales Market Share by Type (2027-2032) Table 24. Global Infectious Coryza Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Doses) Table 25. Global Infectious Coryza Vaccine Revenue by Type (2021-2026) & (K Doses) Table 26. Global Infectious Coryza Vaccine Revenue by Type (2027-2032) & (K Doses) Table 27. Global Infectious Coryza Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Infectious Coryza Vaccine Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Retail Table 30. Major Manufacturers of Online Sale Table 31. Major Manufacturers of Others Table 32. Global Infectious Coryza Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Doses) Table 33. Global Infectious Coryza Vaccine Sales by Application (2021-2026) & (K Doses) Table 34. Global Infectious Coryza Vaccine Sales by Application (2027-2032) & (K Doses) Table 35. Global Infectious Coryza Vaccine Sales Market Share by Application (2021-2026) Table 36. Global Infectious Coryza Vaccine Sales Market Share by Application (2027-2032) Table 37. Global Infectious Coryza Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Doses) Table 38. Global Infectious Coryza Vaccine Revenue by Application (2021-2026) & (K Doses) Table 39. Global Infectious Coryza Vaccine Revenue by Application (2027-2032) & (K Doses) Table 40. Global Infectious Coryza Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global Infectious Coryza Vaccine Revenue Market Share by Application (2027-2032) Table 42. Global Infectious Coryza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 43. Global Infectious Coryza Vaccine Sales by Region (2021-2026) & (K Doses) Table 44. Global Infectious Coryza Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Infectious Coryza Vaccine Sales Forecasted by Region (2027-2032) & (K Doses) Table 46. Global Infectious Coryza Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Infectious Coryza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 48. North America Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 49. North America Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 50. Europe Infectious Coryza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 51. Europe Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 52. Europe Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 53. Asia Pacific Infectious Coryza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 54. Asia Pacific Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 55. Asia Pacific Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 56. South America, Middle East and Africa Infectious Coryza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 57. South America, Middle East and Africa Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 58. South America, Middle East and Africa Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 59. Global Infectious Coryza Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Infectious Coryza Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Infectious Coryza Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Infectious Coryza Vaccine Revenue Market Share by Region (2021-2026) Table 63. Global Infectious Coryza Vaccine Revenue Market Share by Region (2027-2032) Table 64. Boehringer Ingelheim Company Information Table 65. Boehringer Ingelheim Business Overview Table 66. Boehringer Ingelheim Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Boehringer Ingelheim Infectious Coryza Vaccine Product Portfolio Table 68. Boehringer Ingelheim Recent Development Table 69. Ceva Santé Animale Company Information Table 70. Ceva Santé Animale Business Overview Table 71. Ceva Santé Animale Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Ceva Santé Animale Infectious Coryza Vaccine Product Portfolio Table 73. Ceva Santé Animale Recent Development Table 74. Zoetis Company Information Table 75. Zoetis Business Overview Table 76. Zoetis Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Zoetis Infectious Coryza Vaccine Product Portfolio Table 78. Zoetis Recent Development Table 79. Harbin Pharmaceutical Group Company Information Table 80. Harbin Pharmaceutical Group Business Overview Table 81. Harbin Pharmaceutical Group Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Harbin Pharmaceutical Group Infectious Coryza Vaccine Product Portfolio Table 83. Harbin Pharmaceutical Group Recent Development Table 84. Merck Company Information Table 85. Merck Business Overview Table 86. Merck Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Merck Infectious Coryza Vaccine Product Portfolio Table 88. Merck Recent Development Table 89. Plyco Bioengineering Co., Ltd. Company Information Table 90. Plyco Bioengineering Co., Ltd. Business Overview Table 91. Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 93. Plyco Bioengineering Co., Ltd. Recent Development Table 94. Qilu Animal Health Products Co., Ltd. Company Information Table 95. Qilu Animal Health Products Co., Ltd. Business Overview Table 96. Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 98. Qilu Animal Health Products Co., Ltd. Recent Development Table 99. Qingdao Yibang Biological Engineering Co., Ltd. Company Information Table 100. Qingdao Yibang Biological Engineering Co., Ltd. Business Overview Table 101. Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 103. Qingdao Yibang Biological Engineering Co., Ltd. Recent Development Table 104. Shandong Huahong Biological Engineering Co., Ltd. Company Information Table 105. Shandong Huahong Biological Engineering Co., Ltd. Business Overview Table 106. Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 108. Shandong Huahong Biological Engineering Co., Ltd. Recent Development Table 109. Shandong Lvdu Biological Technology Co., Ltd. Company Information Table 110. Shandong Lvdu Biological Technology Co., Ltd. Business Overview Table 111. Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 113. Shandong Lvdu Biological Technology Co., Ltd. Recent Development Table 114. Tianjin Ruipu Biotechnology Co., Ltd. Company Information Table 115. Tianjin Ruipu Biotechnology Co., Ltd. Business Overview Table 116. Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 118. Tianjin Ruipu Biotechnology Co., Ltd. Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Infectious Coryza Vaccine Distributors List Table 122. Infectious Coryza Vaccine Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Infectious Coryza Vaccine Product Image Figure 2. Global Infectious Coryza Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infectious Coryza Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Infectious Coryza Vaccine Sales (2021-2032) & (K Doses) Figure 5. Global Infectious Coryza Vaccine Average Price (US$/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Infectious Coryza Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Monovalent Vaccine Image Figure 9. Bivalent Vaccine Image Figure 10. Trivalent Vaccine Image Figure 11. Global Infectious Coryza Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 12. Global Infectious Coryza Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Infectious Coryza Vaccine Sales Market Share by Type (2021-2032) Figure 14. Global Infectious Coryza Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 15. Global Infectious Coryza Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Infectious Coryza Vaccine Revenue Market Share by Type (2021-2032) Figure 17. Retail Image Figure 18. Online Sale Image Figure 19. Others Image Figure 20. Global Infectious Coryza Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 21. Global Infectious Coryza Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Infectious Coryza Vaccine Sales Market Share by Application (2021-2032) Figure 23. Global Infectious Coryza Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 24. Global Infectious Coryza Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Infectious Coryza Vaccine Revenue Market Share by Application (2021-2032) Figure 26. North America Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 27. North America Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 28. U.S. Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 29. Canada Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 30. Mexico Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 31. Europe Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 32. Europe Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 33. Germany Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 34. France Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 35. U.K. Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 36. Italy Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 37. Netherlands Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 38. Asia Pacific Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 39. Asia Pacific Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 40. China Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 41. Japan Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 42. South Korea Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 43. Southeast Asia Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 44. India Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 45. Australia Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 46. South America, Middle East and Africa Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 47. South America, Middle East and Africa Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 48. Brazil Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 49. South Africa Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 50. Saudi Arabia Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 51. Turkey Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 52. Argentina Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 53. UAE Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 54. Egypt Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 55. Chile Infectious Coryza Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 56. Global Infectious Coryza Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Infectious Coryza Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Infectious Coryza Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. North America Infectious Coryza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Infectious Coryza Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Europe Infectious Coryza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Infectious Coryza Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Infectious Coryza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Infectious Coryza Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Infectious Coryza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Infectious Coryza Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Infectious Coryza Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Monovalent Vaccine
  • Bivalent Vaccine
  • Trivalent Vaccine
Applications
  • Retail
  • Online Sale
  • Others
Companies covered
  • Boehringer Ingelheim
  • Ceva Santé Animale
  • Zoetis
  • Harbin Pharmaceutical Group
  • Merck
  • Plyco Bioengineering Co., Ltd.
  • Qilu Animal Health Products Co., Ltd.
  • Qingdao Yibang Biological Engineering Co., Ltd.
  • Shandong Huahong Biological Engineering Co., Ltd.
  • Shandong Lvdu Biological Technology Co., Ltd.
  • Tianjin Ruipu Biotechnology Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Infectious Coryza Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Infectious Coryza Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Infectious Coryza Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Infectious Coryza Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Infectious Coryza Vaccine Market Dynamics
  1. 2.1 Infectious Coryza Vaccine Industry Trends
  2. 2.2 Infectious Coryza Vaccine Industry Drivers
  3. 2.3 Infectious Coryza Vaccine Industry Opportunities and Challenges
  4. 2.4 Infectious Coryza Vaccine Industry Restraints
3 Infectious Coryza Vaccine Market by Manufacturers
  1. 3.1 Global Infectious Coryza Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Infectious Coryza Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Infectious Coryza Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Infectious Coryza Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Infectious Coryza Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Infectious Coryza Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Infectious Coryza Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Infectious Coryza Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Infectious Coryza Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Infectious Coryza Vaccine Tier 1, Tier 2, and Tier 3
4 Infectious Coryza Vaccine Market by Type
  1. 4.1 Infectious Coryza Vaccine Type Introduction
  2. 4.1.1 Monovalent Vaccine
  3. 4.1.2 Bivalent Vaccine
  4. 4.1.3 Trivalent Vaccine
  5. 4.2 Global Infectious Coryza Vaccine Sales by Type
  6. 4.2.1 Global Infectious Coryza Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Infectious Coryza Vaccine Sales by Type (2021-2032)
  8. 4.2.3 Global Infectious Coryza Vaccine Sales Market Share by Type (2021-2032)
  9. 4.3 Global Infectious Coryza Vaccine Revenue by Type
  10. 4.3.1 Global Infectious Coryza Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Infectious Coryza Vaccine Revenue by Type (2021-2032)
  12. 4.3.3 Global Infectious Coryza Vaccine Revenue Market Share by Type (2021-2032)
5 Infectious Coryza Vaccine Market by Application
  1. 5.1 Infectious Coryza Vaccine Application Introduction
  2. 5.1.1 Retail
  3. 5.1.2 Online Sale
  4. 5.1.3 Others
  5. 5.2 Global Infectious Coryza Vaccine Sales by Application
  6. 5.2.1 Global Infectious Coryza Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Infectious Coryza Vaccine Sales by Application (2021-2032)
  8. 5.2.3 Global Infectious Coryza Vaccine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Infectious Coryza Vaccine Revenue by Application
  10. 5.3.1 Global Infectious Coryza Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Infectious Coryza Vaccine Revenue by Application (2021-2032)
  12. 5.3.3 Global Infectious Coryza Vaccine Revenue Market Share by Application (2021-2032)
6 Global Infectious Coryza Vaccine Sales by Region
  1. 6.1 Global Infectious Coryza Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Infectious Coryza Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Infectious Coryza Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Infectious Coryza Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Infectious Coryza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Infectious Coryza Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Infectious Coryza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Infectious Coryza Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Infectious Coryza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Infectious Coryza Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Infectious Coryza Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Infectious Coryza Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Infectious Coryza Vaccine Revenue by Region
  1. 7.1 Global Infectious Coryza Vaccine Revenue by Region
  2. 7.1.1 Global Infectious Coryza Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Infectious Coryza Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Infectious Coryza Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Infectious Coryza Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Infectious Coryza Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Infectious Coryza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Infectious Coryza Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Infectious Coryza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Infectious Coryza Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Infectious Coryza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Infectious Coryza Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Infectious Coryza Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Infectious Coryza Vaccine Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Ceva Santé Animale
  8. 8.2.1 Ceva Santé Animale Company Information
  9. 8.2.2 Ceva Santé Animale Business Overview
  10. 8.2.3 Ceva Santé Animale Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ceva Santé Animale Infectious Coryza Vaccine Product Portfolio
  12. 8.2.5 Ceva Santé Animale Recent Developments
  13. 8.3 Zoetis
  14. 8.3.1 Zoetis Company Information
  15. 8.3.2 Zoetis Business Overview
  16. 8.3.3 Zoetis Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zoetis Infectious Coryza Vaccine Product Portfolio
  18. 8.3.5 Zoetis Recent Developments
  19. 8.4 Harbin Pharmaceutical Group
  20. 8.4.1 Harbin Pharmaceutical Group Company Information
  21. 8.4.2 Harbin Pharmaceutical Group Business Overview
  22. 8.4.3 Harbin Pharmaceutical Group Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Harbin Pharmaceutical Group Infectious Coryza Vaccine Product Portfolio
  24. 8.4.5 Harbin Pharmaceutical Group Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Infectious Coryza Vaccine Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Plyco Bioengineering Co., Ltd.
  32. 8.6.1 Plyco Bioengineering Co., Ltd. Company Information
  33. 8.6.2 Plyco Bioengineering Co., Ltd. Business Overview
  34. 8.6.3 Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  36. 8.6.5 Plyco Bioengineering Co., Ltd. Recent Developments
  37. 8.7 Qilu Animal Health Products Co., Ltd.
  38. 8.7.1 Qilu Animal Health Products Co., Ltd. Company Information
  39. 8.7.2 Qilu Animal Health Products Co., Ltd. Business Overview
  40. 8.7.3 Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  42. 8.7.5 Qilu Animal Health Products Co., Ltd. Recent Developments
  43. 8.8 Qingdao Yibang Biological Engineering Co., Ltd.
  44. 8.8.1 Qingdao Yibang Biological Engineering Co., Ltd. Company Information
  45. 8.8.2 Qingdao Yibang Biological Engineering Co., Ltd. Business Overview
  46. 8.8.3 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  48. 8.8.5 Qingdao Yibang Biological Engineering Co., Ltd. Recent Developments
  49. 8.9 Shandong Huahong Biological Engineering Co., Ltd.
  50. 8.9.1 Shandong Huahong Biological Engineering Co., Ltd. Company Information
  51. 8.9.2 Shandong Huahong Biological Engineering Co., Ltd. Business Overview
  52. 8.9.3 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  54. 8.9.5 Shandong Huahong Biological Engineering Co., Ltd. Recent Developments
  55. 8.10 Shandong Lvdu Biological Technology Co., Ltd.
  56. 8.10.1 Shandong Lvdu Biological Technology Co., Ltd. Company Information
  57. 8.10.2 Shandong Lvdu Biological Technology Co., Ltd. Business Overview
  58. 8.10.3 Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  60. 8.10.5 Shandong Lvdu Biological Technology Co., Ltd. Recent Developments
  61. 8.11 Tianjin Ruipu Biotechnology Co., Ltd.
  62. 8.11.1 Tianjin Ruipu Biotechnology Co., Ltd. Company Information
  63. 8.11.2 Tianjin Ruipu Biotechnology Co., Ltd. Business Overview
  64. 8.11.3 Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  66. 8.11.5 Tianjin Ruipu Biotechnology Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Infectious Coryza Vaccine Value Chain Analysis
  2. 9.1.1 Infectious Coryza Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Infectious Coryza Vaccine Production Mode & Process
  6. 9.2 Infectious Coryza Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Infectious Coryza Vaccine Distributors
  9. 9.2.3 Infectious Coryza Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst